Julien Kirchgesner is associate professor of gastroenterology at Saint-Antoine hospital, AP-HP, and Sorbonne Université in Paris. He has a PhD in pharmacoepidemiology and did his post-doc in the Division of Pharmacoepidemiology and Pharmacoeconomics of the Brigham and Women's Hospital, Harvard Medical School in Boston (Pr. Sebastian Schneeweiss). His clinical activity is centered on the management of inflammatory bowel disease and his research focuses on the comparative safety and effectiveness of medications in immune-mediated inflammatory diseases and digestive diseases using real-world data. He started in 2024 his own research group in the Pierre Louis Institute of Epidemiology and Public Health (INSERM, Sorbonne University). He has obtained more than 3 million of euros in public funding as PI since 2021, including a European Research Counsil Starting Grant in 2024 to develop a framework leveraging real-world data to clarify the benefit-risk balance of treatment in IBD.